Skip to main content

A commitment for life

A commitment for life

At BPL, we are committed to providing a supply of high quality plasma-derived products worldwide, supporting both healthcare professionals and patients every day.

Find out more

Widely recognised for our human plasma biologics expertise, we are proud of the skills and expertise we have developed over many years.

Find out more

Who We Are

Recognising the importance of plasma and with over 60 years of experience in the industry, BPL supplies high-quality plasma-derived medicines to meet the needs of clinicians, patients and customers globally.

Therapy Areas & Products

BPL manufactures a wide range of products from blood plasma. These products fall broadly into three main therapy areas: immunology, critical care and coagulation disorders. The safety and quality of these plasma products is supported by BPL’s Quality Management Framework.


BPL’s R&D mission is to provide scientific and technical expertise to execute new product pipeline initiatives on time and to discover new products for commercialisation in order to provide a future for the business.

BPL’s commitment to quality is allied to its longstanding investment in its underlying scientific knowledge-base and R&D capability, led by the team of specialists in plasma therapies based in Elstree.

More about R&D


BPL is focused on embracing its environmental, social and governance responsibilities.

BPL is committed to ensuring high standards of governance are maintained across the business, and is increasing its efforts to minimise its environmental impact.

More about responsibility

Featured News

BPL granted licence from the National Medical Products Administration (NMPA) to market ALBUMINEX® 25% product to China

24 January 2022

Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, based in Elstree, UK, announced today that the National Medical Products Administration (NMPA) for China has granted BPL a license to market ALBUMINEX® 25% product to China.

Read full article


20 January 2022

20 January 2022 – Permira, the global private equity firm, today announces that funds advised by Permira, supported by their co-investor, a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), have entered into a partnership with Kedrion’s existing shareholders (the Marcucci family and FSI) to jointly acquire and combine Kedrion and BPL. The combination will create a global player for medicines derived from human blood plasma, which treat patients with rare and life threatening conditions.

Read full article

BPL to support the Immune Deficiency Foundation Research Grant Program

22 October 2021

The IDF Research Grant Program is designed to encourage and support patient-oriented research on primary immunodeficiencies (P.I.), including well-defined research projects with a specified benefit for improving the treatment, health, disease management, or diagnosis of people with P.I. management or diagnosis of people with primary immunodeficiency diseases.

Read full article


We offer excellent career opportunities across our departments.

What we offer

To us, job satisfaction is the biggest benefit to working at BPL.


Whether we have an open vacancy right now or not, we would love to hear from you.


Our Apprenticeship opportunities are a great way to kickstart your career.